Mutations in the KRAS oncogene are dominant features in pancreatic adenocarcinoma (PDA). Since KRAS itself is considered "undruggable", targeting pathways downstream of KRAS is being explored as a rational therapeutic strategy. We investigated the consequences of MEK inhibition in a large PDA cell line panel. Inhibition of MEK activated PI3 kinase in an EGFR-dependent fashion and combinations of MEK and EGFR inhibitors synergistically induced apoptosis. This combinatorial effect was observed in the epithelial but not mesenchymal subtype of PDA. RNA expression analysis revealed predictors of susceptibility to the combination, including E-cadherin, HER3, and the miR200-family of micro-RNAs, while expression of the transcription factor ZEB1 was associated with resistance to the drug combination. Knock-down of HER3 in epithelial-type and ZEB1 in mesenchymal-type PDA cell lines resulted in sensitization to the combination of MEK and EGFR inhibitors. Thus, our findings suggest a new, subtype-specific and personalized therapeutic strategy for pancreatic cancer.
Introduction
The prognosis for patients with pancreatic ductal adenocarcinoma (PDA) remains dismal despite recent modest improvements resulting from optimized use of systemic chemotherapy (1, 2) . Effective therapeutic targeting of key pathways involved in the pathogenesis of this disease could lead to substantial improvements in outcome. The presence of mutations in the KRAS oncogene in more than 90% of PDAs has long been documented (3) . Genetically engineered mouse models of pancreatic cancer have proved the crucial role of this mutation for tumorigenesis and tumor maintenance (4) .
Activating mutations in KRAS result in constitutive signaling through effector pathways (5) . Indeed, presence of phosphorylated ERK and AKT in PDA is associated with poor prognosis (6) . Since mutant KRAS is considered "undruggable" (7) pathways up-and down-stream of RAS have emerged as attractive therapeutic targets (8) . However, clinical results with specific inhibitors of these pathways have been disappointing. For example, the EGFR inhibitor erlotinib was approved by the U.S. Food and Drug Administration for use in PDA in combination with gemcitabine despite only a very modest improvement in median overall survival (9) . Available efficacy data on single agent activity of inhibitors of MEK and PI3K have also demonstrated limited tumor activity (10, 11) . Recent data from our institution demonstrate the existence of molecularly defined sub-types of PDA with differential sensitivity to conventional chemotherapy (12) . Thus, inefficacy of targeted therapies for this disease might be a consequence of failure to understand the subtype-dependent complexities of molecular networks associated with the therapeutic target. Signaling in response to treatment with targeted agents has been demonstrated to result in feedback activation of anti-apoptotic and other important cellular pathways. For example, S6K1-mediated feedback activation of AKT and eIF4E in response to pharmacological inhibition of mTOR resulting in activation of cell survival pathways has been well documented (13, 14) . Similarly, we discovered a novel, EGFR-dependent, feedback loop resulting in PI3K activation in response to inhibition of MEK (15) .
The relevance of this mechanism is highlighted by our finding that interruption of this feedback, e.g. by combining MEK inhibitors with inhibitors of EGFR or PI3K, results in synergistic induction of cell cycle arrest or apoptosis in breast cancer (15, 16) Biomedical). All PDAC cell lines used in this study had activating KRAS mutations, except one -BxPC3, which harbors wild-type KRAS. RAS mutational status was verified by sequencing at UCSF Genomics Core Facility.
Cell growth inhibition assays
Cells were plated in 96 well plates at the density from 3000 to 12000/well depending on the cell line so they are in logarithmic growth at the time of assay. Cells were allowed to attach overnight before being exposed to the drugs for 72 h. Increasing doses of each drug were added in triplicate wells. The final DMSO concentration was 0.2% or less. Cell viability was determined using the CellTiter-Glo (CTG) assay (Promega, Madison, WI). Drug combination studies were designed according to Chou and Talalay (20) . Combined drugs were used at fixed molar ratios. Equitoxic drug doses that produced approximately 50% of growth inhibition in single-agent experiments were chosen to determine an appropriate fixed molar ratio of two combined drugs. For most of the cell lines IC50 was not reached with one or both single agents, therefore the Calcusyn software (Biosoft, Ferguson, MO), commonly used for drug combination studies, was not applicable. The enhancement effect was designated as potentiation when the IC50 from the drug combination treatment was at least 3 fold lower than the lowest IC50 of the single agent.
Apoptosis analysis
Cells were treated with drugs 24 hours after plating and harvested for apoptosis assay at 3 days after drug treatment. Apoptosis was measured in live cells by Annexin V-FITC and propidium iodide (PI) labeling using Apoptosis Detection Kit I (BD Pharmingen) and quantified by Flow Cytometry (FACS Calibur, BD) with FlowJo 7 software. The experiments were done in duplicates and at least 40,000 cells were acquired from every sample for each duplicate. The results were reproduced in three independent experiments.
siRNA transfection
Cells were plated at 20x10^4/ml in 6 well plates and transfected with siRNAs using reverse-transfection protocol with 20nM siRNA and 2.5ul RNAiMax transfection reagent (Invitrogen). 48h after transfection the cells were trypsinized and replated at a required density for the specific assay of drug sensitivity (cell viability or apoptosis. 
Preparation of protein lysates and Western blot analysis
The cells were treated with drugs either in low serum or in full serum conditions 
miRNA expression
In order to analyze whether miRNA were differentially expressed in cell lines sensitive or resistant to a combination of EGFRi/MEKi we analysed miRNA expression in 6 sensitive and 6 resistant cell lines. Total RNA was isolated using mirVana kit (Ambion).
miRNA assays were performed with 100ng total RNA by Nanostring Technologies Tumor sizes were measured twice weekly in two dimensions using a caliper, tumor size (mm 3 ) was calculated as (length x width 2 ) / 2. The doses for drug treatments were chosen as MTD according to the preceding toxicity study in mice bearing HPAF-II xenografts. Animals were monitored for the absence of drug toxicity by measuring body weight twice weekly and monitoring overall activity. To assess for target inhibition, 2 mice from each treatment group were sacrificed at day 3 of treatment, 3 h post dosing.
In vivo xenograft tumor studies
Tumors were excised and protein lysates prepared and subjected to Western blot analysis as described above for cell lines.
Statistical analysis
Statistical analysis was performed using Graph Pad Prism software. An unpaired two-tailed t test was used to determine the significance of change in levels of cell viability and apoptosis between different treatment groups. Data are expressed as mean +/-standard deviation. Statistical analysis to compare tumor sizes in xenograft-bearing mice was done with ANOVA with Bonferroni posttests. P values of <0.05 were considered significant.
Correlation analysis of drug sensitivity.
mRNA expression data of PDA cell lines panel were described previously (12) . sensitivity (sensitive or not) by applying nearest shrunken centroid classification using Pam (24) with ten-fold cross-validation and obtaining the top genes with low misclassification error. We obtained the list of 263 and 29 predictors of sensitivity and resistance, respectively. All calculations were performed using the R language (25) .
Results

MEK inhibition results in negative feedback activation of PI3 kinase, mediated by the EGF receptor
In our previous work, using models of triple-negative breast cancer, we demonstrated that MEK inhibition induces feedback activation of PI3K mediated by the EGF receptor (15) . To investigate whether pathway interactions occur in pancreatic cancer, we treated KRAS mutant (HPAF-II and Panc 10.05) and KRAS-wt (BxPC-3) PDAC cell lines with the MEK inhibitor CI1040, the EGFR inhibitor erlotinib, and their combination at low serum conditions (cell culture medium containing 0.1% fetal bovine serum) in the presence of EGF. As expected, a strong reduction in phosphorylated ERK levels in response to MEK inhibitor treatment was observed (Fig. 1A) . However, MEK inhibition led to enhanced phosphorylation of EGFR and activation of the PI3 kinase pathway, as determined by markedly enhanced protein levels of phosphorylated AKT (pS473), PRAS40 (pT246) and GSK3α/ȕ (pS21/9). MEK inhibitor induced activation of AKT was fully abolished by the EGFR inhibitor erlotinib (Fig. 1A) . Thus, a negative regulatory feedback loop between MEK and the PI3 kinase pathway is operative in PDA cells and depends on activation of the EGF receptor. Fig. 2A ). In 12 cell lines, the potentiation effect was moderate (e.g. Panc10.05; Fig. 2A ). In three cell lines, cell viability was only inhibited by the MEK inhibitor and its combination with EGFR inhibitor had no additional effect (e.g. MiaPaCa-2 cells; Fig. 2A) . Lastly, three cell lines were resistant to both inhibitors as single agents and to their combination (e.g. Panc2.13; Fig. 2A ). The IC50 was calculated for each drug and for their combination using the GraphPad Prism software. If the combined IC50 was at least 7 fold lower (such as for Panc3.27) or 3-6 fold lower (such as for Panc10.05) compared to the lowest IC50 of the single agent, the response was classified as strong synergy/potentiation or as moderate potentiation, respectively. When the combined IC50 was less than 3 fold different than the lowest IC50 of a single drug, 
Interruption of MEK-PI3K feedback results in synergistic inhibition
Almost all moderately responsive cell lines clustered to the interface between the sensitive and resistant cell line clusters (Fig. 2B) . In contrast to data from human primary PDAs, there was no apparent acinar subtype (characterized by expression of chymotrypsin-like elastase family members, and regenerating islet-derived genes, among others (12)).
Three genes (FOXQ1, HER3, and ELF3) identified by us as associated with sensitivity were part of the gene set characterizing the epithelial (classical) subtype of primary human PDAs (12), representing significant overrepresentation (p<0.0004;
Fisher's exact test). These findings indicate that clinically relevant subtypes of PDA respond differently to the combination of MEK/EGFR inhibition. This has implications for further understanding of underlying molecular mechanisms as well as for patient selection strategies in future trials.
Feedback activation of the PI3K pathway resulting from MEK inhibition in
PDA subtypes
We next asked whether the differences in drug sensitivity between epithelial and mesenchymal subtypes were reflected in differential behavior of signal transduction pathways following MEK inhibition. In all cell lines, inhibition of MEK with CI1040 resulted consistently in inhibition of phosphorylation of its effector: ERK. However, in the epithelial-type PDA lines HPAF-II and Panc10.05, increases of phosphorylated AKT levels were detected in cells grown in medium containing 10% FBS following treatment with CI1040 (Fig. 3) , although this effect was less evident compared to low serum conditions with EGF stimulation. In epithelial-type cell lines pAKT was strongly inhibited by erlotinib treatment and completely suppressed by its combination with CI1040. In contrast, the mesenchymal-type PDAC lines showed no induction of pAKT following 
Inhibition of HER3 enhances effects of MEK inhibition in epithelial-type
PDA
The receptor tyrosine kinase HER3 (ERBB3) was found to be among the genes significantly associated with the sensitivity of PDA cell lines to MEKi/EGFRi combination.
Since HER3 is well known to mediate signals from EGFR and HER2 to PI3 kinase, we ascertained whether feedback activation of EGFR following MEK inhibition resulted in had very low basal expression of HER3 protein that was not changed after siRNA knockdown.
In agreement with our hypothesis, epithelial PDA cell lines in which HER3 had been knocked-down showed significantly higher rates of apoptosis in response to single inhibitors or to MEK/EGFR combined inhibition (Fig. 4B) . The drug-induced apoptosis rate in cells treated with triple HER3/MEK/EGFR suppression reached 50 -80% depending on the cell line. Knockdown of HER3 in addition to EGFR inhibition might increase apoptosis induction due to a greater degree of inhibition of signal flow from EGFR to PI3 kinase. Indeed, we observed residual phosphorylation of HER3 following treatment of cells with erlotinib ( Figure 3) . Furthermore, signals from additional receptortyrosine kinases might contribute to this phenomenon. Mesenchymal cell lines (such as Panc2.13), characterized by low levels of HER3, also displayed apoptosis increase, although the overall apoptotic rate was below 10% (Fig.4B) . Therefore, knockdown of 
Suppression of ZEB1 results in sensitization to MEK/EGFR inhibitor combination
Our analysis of molecular predictors of response to the MEK/EGFR inhibitor combination clearly demonstrated that epithelial features significantly correlated with sensitivity. High E-cadherin expression was found to be the strongest predictor of sensitivity, whereas ZEB1 expression was found to be significant predictor of resistance to the MEK/EGFR inhibitor combination. ZEB1 is a well-characterized repressor of Ecadherin transcription and promoter of EMT (28) . ZEB1 also regulates and is regulated by, as part of a double-negative feedback loop, expression of micro-RNAs of the miR200 family (29) . In agreement with this, we found that miR200 family levels were ZEB1 would result in mesenchymal-to-epithelial transition and in sensitization to the inhibitor combination. We utilized two ZEB1 siRNAs that we optimized and validated previously (30) and compared their effect with two controls: non-targeting and Firefly luciferase-targeting siRNAs. Indeed, knock down of ZEB1 in mesenchymal-type PDA cells (Panc2.13, HS766T, and PA-TU8988T) resulted in more than 90% inhibition of ZEB1 protein expression (Fig. 6A) . Following knock-down, noticeable changes in cell morphology resulting in less predominant spindle-cell phenotype were observed (data not shown). This was accompanied by a marked up-regulation of E-cadherin protein expression (Fig.6A) , and activation of pAKT and pHER3 above the background levels in mesenchymal cells (Suppl. Fig. 3 ). In contrast, knock-down of ZEB1 in epithelial cells (which have very low ZEB1 expression) had no effect on E-cadherin levels (Panc10.05 cells, Fig. 6A , HPAF-II cells, Suppl. Fig. 3 ). In agreement with these biochemical findings, knockdown of ZEB1 in mesenchymal-type PDA cells resulted in moderate increases in apoptosis rates in cell treated with single-agent erlotinib or CI1040 while a significant increase in apoptosis rates was observed in cells treated with the combination of both (Fig. 6B) . These phenomena were strongly contrasted by observations in epithelial-type PDA cells that did not demonstrate differences in apoptosis rates with or without knockdown of ZEB1.
Discussion
The RAS oncogene, which is mutated in the vast majority of pancreatic cancers (31) activation of the PI3K pathway in basal-type breast cancer, which utilizes the RAF-MEK-ERK pathway preferentially (15) . Here, we demonstrate that MEK inhibition in pancreatic cancer also leads to EGFR-mediated PI3K activation and, as a result, profound sensitivity to combinations of MEK and EGFR inhibitors in PDA cell line models. These findings occur independent of the KRAS mutation status, in contrast to observations published by others (17) . Our study expands on the published literature substantially as we identify phenotypic differences as crucial predictors of sensitivity to the drug combination, thus setting the stage for patient selection strategies in future trials of this combination. 
resistance to mTOR inhibitors (36) . Our current study expands on these findings by demonstrating that MEK-dependent feedback activation occurs despite presence of KRAS mutations and highlights a role of HER3 in mediating PI3 kinase activation in this context. HER3 is a kinase-deficient member of the HER kinase family containing six tyrosines in its intracellular domain that, when phosphorylated, mediate high-affinity binding to the p85 subunit of PI3 kinase (37) (26, 27) . Interestingly, an inverse relationship between ZEB proteins and miR200 family has been found, revealing a dualnegative feedback loop regulating and maintaining the differentiation state of tumor cells (26, 29) . Previously, it was demonstrated that mesenchymal differentiation of tumor cells promotes resistance to EGFR inhibitors (39, 40) . In agreement with these findings, miRNA signature predictive of sensitivity to EGFR inhibitors is strongly enriched for miRNAs involved in maintaining epithelial differentiation (41) . Here, we demonstrate that induction of mesenchymal-to-epithelial transition by inhibition of ZEB1 expression results in marked sensitization to the combination of MEK and EGFR inhibitors. Re-expression of CDH1 has been demonstrated before to restore sensitivity to EGFR inhibitors (42) .
Thus, it is conceivable that reversal of EMT by repression of ZEB1 restores molecular circuits critical for EGFR activation of anti-apoptotic pathways following MEK inhibition.
The results of these studies hold significant clinical relevance in the treatment of pancreatic cancer, which continues to be a devastating disease for the majority of 
